AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Junctophilin-3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8WXH2

UPID:

JPH3_HUMAN

Alternative names:

Junctophilin type 3; Trinucleotide repeat-containing gene 22 protein

Alternative UPACC:

Q8WXH2; D3DUN2; Q8N471; Q9HDC3; Q9HDC4

Background:

Junctophilin-3, also known as Junctophilin type 3 or Trinucleotide repeat-containing gene 22 protein, plays a crucial role in the formation of junctional membrane complexes (JMCs). These complexes are essential for linking the plasma membrane with the endoplasmic or sarcoplasmic reticulum in excitable cells, facilitating functional cross-talk between the cell surface and intracellular calcium release channels. Specifically, JPH3 is brain-specific, actively participating in neurons involved in motor coordination and memory.

Therapeutic significance:

Junctophilin-3's involvement in Huntington disease-like 2, a neurodegenerative disorder characterized by the loss of neurons in the striatum, underscores its potential as a therapeutic target. Understanding the role of Junctophilin-3 could open doors to potential therapeutic strategies for treating or managing Huntington disease-like 2 and related neurodegenerative conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.